- GSK, Hansoh ADC extends survival in lung cancer study<figure><div><img src="https://imgproxy.divecdn.com/mDk-h3NLB8udDPFuDlI7IPou1i9tJKJYucQXUnhK9vA/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTc3MzEzMjc4LmpwZ…BioPharma Dive · 16d ago↗ source
- German lawmakers pass cost-saving bill that drugmakers say will drive them outGermany’s federal parliament has voted to pass a bill designed to cut domestic healthcare spending that could negatively impact drugmakers, drawing sharp criticism from the country’s main pharmaceu…Endpoints · 16d ago↗ source
- Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injectorPlus, news about Huntington's, Fate Therapeutics and Bausch + Lomb. 🇨🇳 Hansoh touts Phase 3 success for GSK-partnered ADC: The program, called risvutatug rezetecan or Ris-Rez, met its primary e…